



15 December 2016
EMA/CHMP/671386/2016
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Trajenta linagliptin

On 15 December 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Trajenta. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim International GmbH.

The CHMP adopted a change to the existing indication to extend the use of Trajenta in combination with other diabetes medicines. The indication will read as follows:

“Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:

monotherapy

- when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.

combination therapy

- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).”

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

